GAL3 levels measured in ED; furthermore, our follow-up study was serially conducted (30-, 60-, 90-, and 180-day and 12- and 18-month follow-up events (deaths or rehospitalization)). In literature there are very few data on short- and long-term follow-up but all these papers are not serially [3, 4, 27]. Recently published data from three large research trials from HF patients. They demonstrated that elevation of GAL3 levels was significantly predictive of rehospitalization of 30 days from discharge. Moreover those patients of elevation of GAL3 at the time of hospitalization were readmitted within 30 days at three times of rate of patients without GAL3 elevation and the increased risk of hospitalization conferred by GAL3 elevation persisted at 60, 90, and 120 days in the study
The M/M has been doing that for a while now, just his games, point, if there are 2 trades, 1 for 10k shares @ .85 , and 1 for 100 shares at .81at the same time, he 'll show the one for .81,
Jess, If You look at the 1 day basic chart you'll see 10 trades above 5K each, You have 2 for 7500 each , 1 for 12,500 , 1 for 10,000 , 1 for 15,000,
They have 7 days to close above $1.00, if they don't do that, they get a delisting notice from nasdaq, after that BGMD has180 days to regain compliance by finishing above 1.00 for 10 days in a row.,
In T2DM, Gal-3 levels were significantly higher when compared to healthy individuals (median: 12.8 ng/mL). Gal-3 levels were not related to HbA1c, PTH or HOMA variables but were significantly correlated to age Multiple logistic regression analysis including age, eGFR, PTH, NT-proBNP and hsTnT showed that circulating Gal-3 was significantly related to PTH and NT-proBNP.
We observed significantly higher Gal-3 levels in T2DM patients in comparison to healthy volunteers. In T2DM patients, Gal-3 levels were also associated to both NT-proBNP and hsTnT and may represent an emerging risk factor and constitute a new therapeutic target.
The occurrence of heart failure (HF) in patients with type 2 diabetes (T2DM) is frequent and is of ominous prognostic importance. Galectin-3 (Gal-3), is a marker of cardiac fibrosis and remodeling related to both HF with preserved or reduced left ventricular ejection fraction. Our objectives were to determine the circulating levels of Gal-3 in T2DM patients as well as its relationship with established cardiac biomarkers.
Gal-3 levels were measured in 151 T2DM patients with an enzyme-linked immunosorbent assay (BG Medicine). Levels of parathyroid hormone (PTH), N-terminal proBNP (NT-proBNP) and ultra-sensitive troponin T (hsTnT) were also measured. The reference values of each biomarker were determined in a group of 50 normotensive healthy individuals.
First received: November 5, 2013
Last updated: August 4, 2014
Last verified: August 2014
This study has been completed.
Fujirebio Diagnostics, Inc.
J, You and I and many others have been here a very long time, we've seen good and bad days, But I just can't for the life of me figure out what the heck is taking them soooooo long, its been a minimum of 173 days and possibly up to 199 days, This is a very long time IMHO, Hope all is well.
For such behavior, Instead of wasting OUR Money on trips to Europe, They should pay more attention to what's going on in the good old USA, This Company Stinks and I've them know it in no uncertain terms, A GREAT Product with a BOD's that suck
Jess, once they receive the letter, they will have a minimum of 6 months and up to a year to get into compliance, compliance is any 10 days in a row over $1.00 within a year, no worries about that, as for R/S, if the 510K goes well, there will be no chance of that, remember, there are only around 36m OS, That's not much for a Bio stock.
AGAIN, hope this company has enough common sense to understand that, But I doubt they have any common sense at all when it comes to this stock. Dumb #$%$,es when it comes to shareholders
METHODS AND RESULTS:
A total of 706 patients with SCAD and a history of acute coronary syndrome (ACS) were analyzed over a follow up period of 2.2 years. The primary endpoint was the occurrence of an ischemic event (any SCA, stroke or transient ischemic attack), heart failure, or death. A clinical risk scale derived from the LIPID study significantly predicted the development of the primary endpoint, with an area under the ROC curve (Receiver Operating Characteristic) A composite score was developed by adding the scores of the LIPID and scale decile levels of MCP -1, galectin -3 and NT-proBNP. The predictive value improved with an area under the curve . A score greater than 21.5 had a sensitivity of 74% and a specificity of 61% for the development of the primary endpoint
Plasma levels of MCP-1, galectin -3 and NT-proBNP improve the ability of the LIPID clinical scale to predict the prognosis of patients with SCAD.
At present, there is no tool validated by scientific societies for risk stratification of patients with stable coronary artery disease (SCAD). It has been shown that plasma levels of monocyte chemoattractant protein-1 (MCP-1), galectin-3 and pro-B-type natriuretic peptide amino-terminal (NT-proBNP) have prognostic value in this population.
To analyze the prognostic value of a clinical risk scale published in Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study and determining its predictive capacity when combined with plasma levels of MCP-1, galectin-3 and NT-proBNP in patients with SCAD.
I cant for the life of me understand why BG Medicine does not think this news is worthy of a Press Release, This is the frustration most of us feel with this company,
Conclusions - Elevated galectin-3 was found to be an independent predictor of adverse
HF outcome in patients with mildly symptomatic HF. A significant interaction of device
randomization group with pre-implantation galectin-3 level was detected, with HF
patients having the highest baseline galectin-3 levels deriving a disproportionately larger
benefit from CRT-D therapy. = Cardiac Resynchronization Therapy
Boston Scientific Makes Defibrillator.s , BG Medicine Has A Patent For Cardiac Resynchronization Therapy, OH BOY THIS COULD GET INTERESTING
Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial––Cardiac Resynchronization Therapy)
Craig M. Stolen, PhD Aram Adourian, PhD Timothy E. Meyer, PhD Kenneth M. Stein, MD Scott D. Solomon, MD
PII: S1071-9164(14)00695-2 DOI: 10.1016/j.cardfail.2014.07.018 Reference: YJCAF 3369
To appear in: Journal of Cardiac Failure
Received Date: 7 November 2013 Revised Date: 25 July 2014 Accepted Date: 29 July 2014
Plasma Galectin-3 and Heart Failure Outcomes in MADIT-CRT
(Multicenter Automatic Defibrillator Implantation Trial--Cardiac
Craig M. Stolen, PhD1, Aram Adourian, PhD2, Timothy E. Meyer, PhD1, Kenneth
M. Stein, MD1, and Scott D. Solomon, MD3
1 Boston Scientific Corporation, St Paul, MN;
2 BG Medicine, Inc. Waltham, MA;
3 Department of Medicine, Brigham and Women’s Hospital, Boston, MA
Short Title: Galectin-3 in MADIT-CRT
Funding: This work was supported by Boston Scientific Corporation and BG Medicine,
Correspondence: Craig M. Stolen, Boston Scientific Corporation
Galectin-3 is secreted by activated macrophages and has been linked to myocardial fibrosis, hypertrophy, and remodeling, and it has prognostic value in both acute and chronic heart failure. Importantly, when measured serially, galectin-3 was found to add incremental prognostic value in a vigorously adjusted model. Furthermore, there may be particularly important places where galectin-3 will have a strong role, such as in patients with heart failure and preserved ejection fraction—an important population accounting for up to half of the affected patients with heart failure, and where galectin-3 was incrementally prognostic. Rather than considering galectin-3 only as a prognostic tool, in the future it may be a target of therapy. With the emergence of specific galectin-3 inhibitors, it may be the biomarker that will be used as a tool to decide on individualized care with these agents.
and were also significantly and positively correlated to BNP concentrations Gal-3 values higher than 19.2ng/mL were predictive of long-term cardiovascular death in patients with systolic HF and also provided incremental prognostic information to BNP testing. In addition, Gal-3 testing was estimated to save DRG in comparison to standard of care.
Our results demonstrated the clinical validity of the ARCHITECT Gal-3 automated immunoassay for the risk stratification of HF patients. The automation of Gal-3 testing was also cost-effective and might help to preserve hospital budget.